Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 54Genitourinary 34Other hematologic neoplasm 15Plasma cell 11Dermatologic 4Myeloid 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Prednisone × Sarcoma × Clear all
NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡